Myriad Genetics (NASDAQ:MYGN) Cut to “Market Perform” at Leerink Partners
Myriad Genetics (NASDAQ:MYGN – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Monday, MarketBeat reports. They currently have a $21.00 target price on the stock, down from their prior target price of $30.00. Leerink Partners’ price […]
More Stories
Is Rosario Tijeras Season 5 Renewed? Release Date, Cast, and Synopsis
The popular Mexican television series or opera drama, Rosario Tijeras, is returning for its 5th season after getting a positive...
Pokémon Horizons Season 3: Release Date, Trailer, and Spoiler
Fan of the Pokémon series and desperately waiting for its release? Good News! Pokémon Horizons Season 3 is coming up...
Drew Carey Blast on Mayor Candidate, Spencer Pratt, called him a ‘Serial Scammer’
Drew Carey, a popular host, actor, and producer, has slammed the Los Angeles mayoral candidate, Spencer Pratt. On May 24,...
15+ Best Thrillers on Netflix: Movies and Television Series
Do you love to watch thriller shows and movies? Here, in this blog, I have mentioned the best thrillers on...
Maternal Instinct: A True Crime Documentary will release on Netflix this June
Do you also like true crime documentaries like The Investigation of Lucy Letby and Should I Marry a Murderer? Good...
You Can’t Skip These Roblox Competitors
Roblox has introduced millions of joystick junkies and developers to the world for creating amazing games and igniting their creative...
